VYNE Therapeutics (VYNE) Cash from Investing Activities (2017 - 2026)

VYNE Therapeutics' Cash from Investing Activities history runs 10 years deep, the most recent figure standing at $4.7 million for Q1 2026.

• Quarterly Cash from Investing Activities fell 76.3% year-over-year to $4.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $41.9 million (down 10.31% YoY) and the FY2025 annual result came in at $37.4 million, up 59.93% from the prior year.
• Cash from Investing Activities was $4.7 million for Q1 2026 at VYNE Therapeutics, up from $4.7 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $19.8 million in Q1 2025 and bottomed at -$62.4 million in Q4 2023.
• A 5-year average of $907000.0 and a median of $4.7 million in 2025 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities tumbled 6235500.0% — and 2025, when it surged 655.65%.
• VYNE Therapeutics' Cash from Investing Activities stood at $1000.0 in 2022, then tumbled by 6235500.0% to -$62.4 million in 2023, then surged by 120.43% to $12.7 million in 2024, then sank by 63.3% to $4.7 million in 2025, then rose by 0.53% to $4.7 million in 2026.
• Business Quant data shows VYNE's Cash from Investing Activities at $4.7 million in Q1 2026, $4.7 million in Q2 2025, and $19.8 million in Q1 2025.